Lundbeck Wins Japan Approval for Migraine Drug Vyepti, First Solo Launch
Valby, Denmark – – September 18, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.
MHLW clears the only IV CGRP-targeted migraine preventive on the market
Eptinezumab remains the sole intravenous CGRP-targeted therapy approved for migraine prevention, now available in more than 30 markets worldwide following the Japanese clearance. The drug was first approved by the U.S. FDA in February 2020, followed by the European Commission in January 2022 and, most recently, South Korea.